Obesity surgery · 2026
Prevalence of Psychotropic Drug Treatment Interventions in Patients Undergoing Metabolic and Bariatric Surgery: A Retrospective Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wever Susannah Anna-Maria Leilani, Sizoo Dionne, van Roon Eric Nico, Cheung Victoria Hiu Yeung, Damhof Michiel Adriaan, Emous Marloes, Oortgiesen Berdine Emma
Аннотация
BACKGROUND: The pharmacokinetics of oral psychotropic drugs can change after metabolic and bariatric surgery (MBS), affecting drug exposure. Given the risk of psychiatric decompensation, patients using psychotropic medications constitute a high-risk group requiring careful post-MBS monitoring. In particular, lithium, tricyclic antidepressants (TCAs), and clozapine are of concern because of their well-established dose-effect relationships, susceptibility to MBS-related exposure changes, and suitability for therapeutic drug monitoring (TDM). This study aimed to examine the prevalence of treatment interventions related to these medications in bariatric patients to prevent drug-related problems such as under- or overexposure requiring dosage adjustments or drug discontinuation.
METHODS: In this retrospective study, patient records from January 2017 to December 2023 were reviewed. Patients who underwent MBS and were using lithium, TCAs (amitriptyline, clomipramine, dosulepin, doxepin, imipramine, maprotiline, nortriptyline), and/or clozapine were included. Baseline characteristics, treatment interventions, and available drug plasma concentrations were collected preoperatively and up to one year postoperatively.
RESULTS: A total of 163 patients were included. Psychotropic drug adjustments were observed in 27 patients (16.6%) within the first year following MBS. Both pre- and postoperative drug plasma concentrations were available for three patients (1.8%). Three patients experienced worsening of psychiatric symptoms that necessitated hospitalization or intensive monitoring. No statistically significant differences in intervention rates were observed among patients with psychiatric disorders or pain.
CONCLUSION: Although only a minority of patients required psychotropic drug treatment interventions, monitoring psychotropic drug treatment is essential for safe and effective treatment post-MBS. Greater attention is needed regarding altered drug exposure, and plasma concentration monitoring may help optimize psychotropic pharmacotherapy in these patients.
METHODS: In this retrospective study, patient records from January 2017 to December 2023 were reviewed. Patients who underwent MBS and were using lithium, TCAs (amitriptyline, clomipramine, dosulepin, doxepin, imipramine, maprotiline, nortriptyline), and/or clozapine were included. Baseline characteristics, treatment interventions, and available drug plasma concentrations were collected preoperatively and up to one year postoperatively.
RESULTS: A total of 163 patients were included. Psychotropic drug adjustments were observed in 27 patients (16.6%) within the first year following MBS. Both pre- and postoperative drug plasma concentrations were available for three patients (1.8%). Three patients experienced worsening of psychiatric symptoms that necessitated hospitalization or intensive monitoring. No statistically significant differences in intervention rates were observed among patients with psychiatric disorders or pain.
CONCLUSION: Although only a minority of patients required psychotropic drug treatment interventions, monitoring psychotropic drug treatment is essential for safe and effective treatment post-MBS. Greater attention is needed regarding altered drug exposure, and plasma concentration monitoring may help optimize psychotropic pharmacotherapy in these patients.